CHICAGO — Fibrosis and macular atrophy increase the risk for vision loss in patients on long-term anti-VEGF therapy for neovascular age-related macular degeneration, according to a study.
“There is no doubt that visual acuity improves with anti-VEGF treatment, at least for the first 3 years,” Giovanni Staurenghi, MD, said at Retina Subspecialty Day at the American Academy of Ophthalmology meeting. “We also know that it decreases over the years. One of the reasons could be fibrosis or macular atrophy.”
Staurenghi and colleagues assessed the cumulative incidence of